Phaseline

Targets › NKG2C

NKG2C (NKG2-C type II integral membrane protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2030.

Immune activating receptor involved in self-nonself discrimination. In complex with KLRD1 on cytotoxic lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib HLA-E loaded with signal sequence-derived peptides from non-classical MHC class Ib HLA-G molecules, likely playing a role in the generation and effector functions of adaptive natural killer (NK) cells and in maternal-fetal…. (UniProt, P26717)

Open in Phaseline: the race on NKG2C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Masonic Cancer Center, University of MinnesotaAdaptNK
Allogeneic KIR-HLA mismatched NK cell infusion enriched for CMV-induced adaptive NK cells
NCAM1, NKG2CPhase 1Relapsed Adult AMLMar 2030

Conditions

Relapsed Adult AML (1)

Modalities

mixed (1)

Companies

Masonic Cancer Center, University of Minnesota (1)

Related targets

NCAM1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.